Or­biMed, J&J back $24M A round for mi­cro­bio­me start­up; Sang­amo, Pfiz­er win FDA fast track

→ A new mi­cro­bio­me start­up, Is­rael’s Bio­mX, has raised $24 mil­lion in a Se­ries A — Or­biMed, John­son & John­son In­no­va­tion and Take­da Ven­tures were in on the round, with par­tic­i­pa­tion from Sev­en­ture Part­ners, Mi­rae­As­set, SBI Japan-Is­rael In­no­va­tion Fund and oth­er Eu­ro­pean in­vestors. Bio­mX is a pre­clin­i­cal biotech set­ting the stage for its first hu­man study in the field of gut bi­ol­o­gy, which has at­tract­ed a num­ber of new play­ers over the past few years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER